drugset
drugset / Trial / NCT00093275

HP184 in Chronic Spinal Cord Injury Subjects

NCT00093275 ↗

Phase 2 Completed 262 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether HP184 is effective in the treatment of chronic spinal cord injury (CSCI).

Timeline

Start
2004-10
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerispirdine Small molecule — Oral

Indications

spinal cord injury